AzTrials
AzTrials

NEC - Necrotizing EnterocolitisNCT03091907

Long-term Consequences of Necrotizing Enterocolitis in the Newborn Period

An observational study of NEC - Necrotizing Enterocolitis and Complications, run by Gorm Greisen at 2 sites in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim The aim of this study is to determine consequences at school age of the diagnosis of NEC in the neonatal period. Methods This is a case-control study, with case-group being children born in Denmark with a history of NEC and control-group being age-, gestational age- and year of birth matched children born in… Read more about this study

Who is it for?
Ages 5 to 15 years
How many people
400 participants
Where
2 sitesDenmark
Study dates
5 Aug 2017to 1 Aug 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 15 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Case-group will include all surviving children born in Denmark between 1st of January 2002 and 31st of December 2011 with an ICD-10 diagnosis of NEC (DP77.9) at discharge. Matching each child with a history of NEC to two children with no history of NEC by gestational age, year of birth and birthweight will form the control group. Matching criteria's have been chosen to balance prematurity and age at follow-up between case and control-group.

Who may be able to join

  • Born from 1st of January 2002 to 31st of December 2011
  • ICD-10 diagnosis of NEC (DP77.9)
  • Survival at follow-up
  • Response to questionnaire
  • Born from 1st of January 2002 to 31st of December 2011
  • Matched by year of birth, birthweight and gestational age to children in case-group
  • Survival at follow-up
  • Response to questionnaire

Who cannot join

  • Death before follow-up
  • Non-responders to questionnaire

Trial locations and contacts

2 sites in 1 country.

Denmark2 sites
  • Neonatalklinikken, Rigshospitalet

    Copenhagen, Capital Region, 2100

  • Department of Neonatology, Rigshospitalet

    Copenhagen, 2100

Other trials in Denmark

About this study

Official title: Long-term Consequences of Necrotizing Enterocolitis in the Newborn Period: Follow-up at School Age, a Case-control Study

Aim

The aim of this study is to determine consequences at school age of the diagnosis of NEC in the neonatal period.

Methods

This is a case-control study, with case-group being children born in Denmark with a history of NEC and control-group being age-, gestational age- and year of birth matched children born in Denmark with no history of NEC.

Primary outcome

Abnormal or borderline 'total difficulties score' in the strenghts-and-difficulties-questionnaire as assessed by parents.

Read the detailed description

Rationale

Knowledge of the long-term complications related to necrotizing enterocolitis (NEC) in the neonatal period is essential, when clinicians are counseling parents about the risk for complications following NEC. When deciding upon a follow-up strategy for the infant after discharge, this knowledge is also crucial. If the infant has an increased risk for complications later in life, a closer follow up is important to assure proper handling of complications.

So far, a definite conclusion regarding long-term complications of NEC has not been made. A systematic review including ten studies, have shown a significantly increased risk for neurodevelopmental impairment in NEC children. However, the median follow-up time did not exceed two years and may not reflect the true long-term complications. The ORACLE Children Study investigated neurodevelopmental impairments in children with a history of NEC at 7,5 year follow-up and found no increased risk.

No review has been published regarding growth impairments and so far, available studies have a less than three year follow-up period and are reporting conflicting results.

Gastrointestinal morbidities are even less investigated and reports no association with NEC within three years follow-up. However, the ORACLE Children Study found increased risk of bowel problems at 7,5 years follow-up in children with a history of NEC.

The Oracle Children Study and Roze et al reported behavioural problems in up to 30% of children with a history of NEC at school age, but no statistic significance was found when compared to a control-group.

Further studies investigating the outcome of NEC-children at school age are needed.

Objectives

The investigators plan to conduct a retrospective parental-questionnare study, to determine the long-term complications related to the diagnosis of NEC at school age (5-15 years of age).

Methods

This is a case-control study. Case-group will include all surviving children born in Denmark between 1st of January 2002 and 31st of December 2011 with an international classification of diseases (ICD-10) diagnosis of NEC at discharge. Matching each child with a history of NEC to two children with no history of NEC by gestational age, year of birth and birthweight will form the control group. Matching criteria's have been chosen to balance prematurity and age at follow-up between case and control-group. Parental follow-up questionnaires regarding complications will be sent to all parents of cases and controls.

Clinical data on the children, regarding birth and neonatal history, will be obtained and used in a mixed regression model to adjust for possible confounders.

Primary outcome

Abnormal or borderline 'total difficulties score' in the strenghts-and-difficulties-questionnaire as assessed by parents.

Secondary outcomes

  1. Severe cerebral palsy (GMFCS III-IV)
  2. Head circumference as measured by parents
  3. Height as measured by parents
  4. Abdominal symptoms resulting in significant absence from school as reported by parents
  5. Diarrhoea within the last six months
  6. Constipation within the last six months

Power calculation

The sample size for the case group was estimated to include 200 children with NEC (after a no-response drop out of 20%) and in the control group 300 children without NEC, with a 1:2 match ratio and the assumption that the response rate will be lower in the control group., i.e. 250 parents of children with NEC and 500 parents of control children will be contacted.

SDQ total score Assuming 30% prevalence of abnormal or borderline scores for 'total difficulties' in the strength-and-difficulties-questionnaire in NEC-survivors, compared to an assumed 20% in controls (19), this study will detect the difference with a power of 72% at a 5% significance level.

Severe cerebral palsy (GMFCS score III-V) Assuming a 20% prevalence (9) of severe cerebral palsy in NEC-survivors compared to an assumed 10% in controls (22) this study will detect the difference with a power of 87% at a 5% significance level.

Head circumference The power calculation on our cohort shows that we, at a 5% significance level, can detect the difference in mean head circumference at 0.3 standard-deviations or more, with a power of 90%.

Analysis plan

Primary outcome: a p-value < 0.05 will be considered significant. To determine a difference in SDQ-scores between case- and control group, Chi-squared test or Fischer's Exact test will be used as appropriate.

Secondary outcome: a p-value < 0.01 will be considered significant. Differences in 'height', 'head circumference' and 'absence from school due to abdominal symptoms' will be investigated by t-test or Mann-Whitney's test as appropriate. 'Severe cerebral palsy', 'diarrhoea' and 'constipation' will be analyzed by Chi-squared test or Fischer´s Exact test as appropriate.

At first, an unadjusted analysis will be performed to investigate differences in primary and secondary outcome. Secondly, a mixed regression model will be used to adjust for possible confounders

Keywords
Necrotizing enterocolitis, Followup, Neurodevelopmental impairments, Growth impairments, Gut function, Behavioural impairments
Medical subject headings
Enterocolitis, Necrotizing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03091907
Study groupRoleWhat they receive
CaseChildren with a history of necrotizing enterocolitis
controlChildren with no history of necrotizing enterocolitis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Behavioral impairments

    Strength and Difficulties Questionnaire (SDQ). Behavioral impairment (yes/no) is defined if the child has an abnormal or borderline score for the 'total difficulties score'.

    Measured: 6-15 years

Secondary outcomes (6)
  1. Cerebral palsy

    We will dichotomize between non/mild cerebral palsy defined as lower score than III in the Gross Motor Function Classification System and moderate/severe cerebral palsy defined as scoring III or higher.

    Measured: 5-15 years

  2. Height

    Height in cm as measured by parents. 'low height-for-age' defined as height in cm less than - 2 standard deviations.

    Measured: 5-15 years

  3. Head circumference

    Head circumference in cm as measured by parents.

    Measured: 5-15 years

  4. Absence from school due to abdominal symptoms

    Defined as number of days within the last six months, where the child has stayed home from school due to abdominal symptoms including pain, diarrhea, constipation, frequent bowel movements etc.

    Measured: 5-15 years

  5. Constipation

    Defined as wether or not the child, within the last six months, have had stools scoring 1 or 2 on the Bristol Stool Scale.

    Measured: 5-15 years

  6. Diarrhoea

    Defined as wether or not the child, within the last six months, have had stools scoring 5-7 on the Bristol Stool Scale.

    Measured: 5-15 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2017
  2. Study start5 Aug 2017
  3. Primary completion1 Jan 2018
  4. Study completion1 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03091907
Sponsor's protocol ID
2012-58-0004
Status last verified
Dec 2018
First submitted
21 Mar 2017
Last updated
5 Dec 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of NEC - Necrotizing Enterocolitis and Complications, run by Gorm Greisen at 2 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Behavioral impairments (time frame: 6-15 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in